Dyslipidemia – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Dyslipidemia – Drugs In Development, 2023’, provides an overview of the Dyslipidemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyslipidemia
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
89bio IncABIONYX Pharma SA
Addpharma Inc
Akeso Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
BCWorld Pharm Co Ltd
Beijing GeneCradle Technology Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing University of Chinese Medicine
Bio-Thera Solutions Ltd
BioRestorative Therapies Inc
CannaLean Biotechs Ltd
Cardax Inc
Celltrion Inc
Centaurus Therapeutics Inc
Centeer BioTherapeutics Ltd Co
Central Drug Research Institute
China Pharmaceutical University
Chinese Academy of Medical Sciences and Peking Union Medical College
Chinese Academy of Sciences
Chong Kun Dang Pharmaceutical Corp.
Columbia University
CRISPR Therapeutics AG
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
CVI Pharmaceuticals Ltd
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dalian Wista Pharmaceutical Co Ltd
Delivra Corp
DongKoo Bio & Pharma Co Ltd
Dongkwang Pharma Co Ltd
Eccogene (Shanghai) Co Ltd
Eddingpharm Inc
Eli Lilly and Co
EmendoBio Inc
Esperion Therapeutics Inc
FUDAN University
FunPep Co Ltd
Genuone Science Co Ltd
GENUONE Sciences Inc
Golden Biotechnology Corp
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Hepagene Therapeutics Shanghai Inc
HighTide Therapeutics Inc
HK inno.N Corp
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
inCerebro Co Ltd
Inovio Pharmaceuticals Inc
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Korea United Pharm Inc
Kotobuki Pharmaceutical Co Ltd
Kowa Co Ltd
Kuhnil Pharmaceutical Co Ltd
Kyttaro Ltd
Liaoning University of Traditional Chinese Medicine
Liid Pharmaceuticals Inc
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Marea Therapeutics
MediciNova Inc
Mochida Pharmaceutical Co Ltd
NewAmsterdam Pharma Company NV
Northeast Ohio Medical University
NorthSea Therapeutics BV
NovalGen Ltd
Novartis AG
Novo Nordisk AS
Nubiyota LLC
NuSirt Biopharma Inc
NVP Healthcare Co Ltd
Omeros Corp
OrsoBio Inc
Osaka University
Peking University
Purpose Bio Inc
Regeneron Pharmaceuticals Inc
Rivus Pharmaceuticals Inc
Runjia (Suzhou) Pharmaceutical Technology Co Ltd
Saliogen Therapeutics Inc
Seoul National University Hospital
Sequor Pharmaceuticals LLC
Shanghai Argo Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Minwei Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Sirnaomics Ltd
SJT Molecular Research SL
SUNY Downstate Medical Center
Suzhou Ribo Life Sciences Co Ltd
Sveikatal Inc
Tetranov International Inc
The United Laboratories International Holdings Ltd
Torrent Pharmaceuticals Ltd
University College of Medical Sciences
University of Cincinnati
University of Wisconsin Madison
Viking Therapeutics Inc
Visirna Therapeutics HK Ltd
Waterstone Pharmaceuticals (Wuhan) Ltd
Yooyoung Pharm Co Ltd
Yungjin Pharm Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd
Zydus Lifesciences Ltd